B
Bohuslav Melichar
Researcher at Charles University in Prague
Publications - 323
Citations - 16978
Bohuslav Melichar is an academic researcher from Charles University in Prague. The author has contributed to research in topics: Neopterin & Cancer. The author has an hindex of 38, co-authored 292 publications receiving 12110 citations. Previous affiliations of Bohuslav Melichar include Palacký University, Olomouc.
Papers
More filters
Journal ArticleDOI
Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma
Robert J. Motzer,Nizar M. Tannir,David F. McDermott,Osvaldo Arén Frontera,Bohuslav Melichar,Toni K. Choueiri,Elizabeth R. Plimack,Philippe Barthélémy,Camillo Porta,Saby George,Thomas Powles,Frede Donskov,V. Neiman,V. Neiman,Christian Kollmannsberger,Pamela Salman,Howard Gurney,Robert E. Hawkins,Alain Ravaud,Marc-Oliver Grimm,Sergio Bracarda,Carlos H. Barrios,Yoshihiko Tomita,Daniel Castellano,Brian I. Rini,Allen C. Chen,Sabeen Mekan,M. Brent McHenry,Megan Wind-Rotolo,Justin Doan,Padmanee Sharma,Hans J. Hammers,Hans J. Hammers,Bernard Escudier +33 more
TL;DR: Overall survival and objective response rates were significantly higher with nivolumab plus ipilimumab than with sunitinib among intermediate‐ and poor‐risk patients with previously untreated advanced renal‐cell carcinoma.
Journal ArticleDOI
Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial
Bernard Escudier,Anna Pluzanska,Piotr Koralewski,Alain Ravaud,Sergio Bracarda,Cezary Szczylik,Christine Chevreau,Marek Filipek,Bohuslav Melichar,Emilio Bajetta,Vera Gorbunova,Jacques-Olivier Bay,Istvan Bodrogi,Agnieszka Jagiełło-Gruszfeld,Nicola Moore +14 more
TL;DR: In this article, the authors investigated the combination treatment of the humanised anti-VEGF monoclonal antibody bevacizumab with interferon alfa, and reported a significant improvement in progression-free survival.
Journal ArticleDOI
Pembrolizumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma
Brian I. Rini,Elizabeth R. Plimack,Viktor Stus,Rustem Gafanov,Robert E. Hawkins,Dmitry Nosov,Frédéric Pouliot,Boris Alekseev,Denis Soulières,Bohuslav Melichar,Ihor Vynnychenko,Anna Kryzhanivska,Igor Bondarenko,Sergio J Azevedo,Delphine Borchiellini,Cezary Szczylik,Maurice Markus,Raymond S. McDermott,Jens Bedke,Sophie Tartas,Yen-Hwa Chang,Satoshi Tamada,Qiong Shou,Rodolfo F. Perini,Mei Chen,Michael B. Atkins,Thomas Powles +26 more
TL;DR: Treatment with pembrolizumab plus axitinib resulted in significantly longer overall survival and progression‐free survival, as well as a higher objective response rate, than treatment with sunitin ib among patients with previously untreated advanced renal‐cell carcinoma.
Journal ArticleDOI
Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048) : a randomised, open-label, phase 3 study
Barbara Burtness,Kevin J. Harrington,Richard Greil,Denis Soulières,Makoto Tahara,Gilberto de Castro,Amanda Psyrri,Neus Baste,Prakash Neupane,Åse Bratland,Thorsten Fuereder,Brett G.M. Hughes,Ricard Mesia,Nuttapong Ngamphaiboon,Tamara Rordorf,Wan Zamaniah Wan Ishak,Ruey-Long Hong,René González Mendoza,Ananya Roy,Yayan Zhang,Burak Gumuscu,Jonathan D. Cheng,Fan Jin,Danny Rischin,Danny Rischin,Guillermo Lerzo,Marcelo Tatangelo,Mirta Varela,J. J. Zarba,Michael Boyer,Hui K Gan,Bo Gao,Brett Hughes,Girish Mallesara,Anne W. Taylor,Martin Burian,Carlos H. Barrios,Dalvaro Oliveira de Castro Junior,Gilberto de Castro,Fabio Franke,Gustavo Girotto,Iane Pinto Figueiredo Lima,Ulisses Ribaldo Nicolau,Gustavo Dix Junqueira Pinto,Lucas Vieira dos Santos,Ana Paula Victorino,Neil Chua,Felix Couture,Richard Gregg,Aaron R. Hansen,John Hilton,Joy McCarthy,Rodrigo Ascui,Pablo Gonzalez,Luis Villanueva,Marco Torregroza,Angela Zambrano,Petra Holeckova,Zdenek Kral,Bohuslav Melichar,Jana Prausova,Milan Vosmik,Maria Andersen,Niels Gyldenkerne,Hannes Jurgens,Kadri Putnik,Petri Reinikainen,Viktor Gruenwald,Simon Laban,Gerasimos Aravantinos,Ioannis Boukovinas,Vassilis Georgoulias,Dora Kwong,Yousuf Al-Farhat,Tibor Csoszi,Jozsef Erfan,Geza Horvai,Laszlo Landherr,Éva Remenár,Agnes Ruzsa,Judit Szota,Salem Billan,Iris Gluck,Orit Gutfeld,Aron Popovtzer,Marco Benasso,Simona Bui,Vittorio Ferrari,Lisa Licitra,Franco Nolè,Takashi Fujii,Yasushi Fujimoto,Nobuhiro Hanai,Hiroki Hara,Koji Matsumoto,Kenji Mitsugi,Nobuya Monden,Masahiro Nakayama,Kenji Okami,Nobuhiko Oridate,Kiyoto Shiga,Yasushi Shimizu,Masashi Sugasawa,Masanobu Takahashi,Shunji Takahashi,Kaoru Tanaka,Tsutomu Ueda,Hironori Yamaguchi,Tomoko Yamazaki,Ryuji Yasumatsu,Tomoya Yokota,Tomokazu Yoshizaki,Iveta Kudaba,Zinaida Stara,Soon Keat Cheah,Jose Aguilar Ponce,Carlos Hernandez Hernandez,Francisco Medina Soto,Jan Buter,Ann Hoeben,Sjoukje F. Oosting,Karijn P M Suijkerbuijk,Aase Bratland,Marianne Brydoey,Renzo Alvarez,Luis Mas,Priscilla Caguioa,John Querol,Eugenio Emmanuel Regala,Maria Belen Tamayo,Ellie May Villegas,Andrzej Kawecki,Andrey Karpenko,Arkadiy Klochikhin,Alexey Smolin,Oleg Zarubenkov,Boon Cher Goh,Graham Cohen,Johanna du Toit,Christa Jordaan,Gregory Landers,Paul Ruff,Waldemar Szpak,Neonyana Tabane,Irene Brana,Lara Carmen Iglesias Docampo,Javier Lavernia,Edvard Abel,Valentina Muratidu,Niels Nielsen,Valerie Cristina,Sacha Rothschild,Hung Ming Wang,Muh Hwa Yang,Su Peng Yeh,Chia Jui Yen,Nopadol Soparattanapaisarn,Virote Sriuranpong,Sercan Aksoy,Irfan Cicin,Meltem Ekenel,Hakan Harputluoglu,Ozgur Ozyilkan,Kevin J. Harrington,Sanjiv S. Agarwala,Haythem Ali,Robert Alter,Daniel Anderson,Justine Bruce,Nicholas Campbell,Miguel Conde,John F. Deeken,William Edenfield,Lawrence E. Feldman,Elizabeth Gaughan,Basem Goueli,Balazs Halmos,Upendra P. Hegde,Brian Hunis,Robert Jotte,Anand B. Karnad,Saad A. Khan,Noel Laudi,Douglas Laux,Danko Martincic,Steven McCune,Dean McGaughey,Krzysztof Misiukiewicz,Deborah Mulford,Eric Nadler,Johannes Nunnink,James Ohr,Meaghan O'Malley,Brian Patson,Doru Paul,Elizabeta Popa,Steven Francis Powell,Rebecca Redman,Vincent Rella,Chaio Rocha Lima,Abirami Sivapiragasam,Yungpo Su,Ammar Sukari,Stuart Wong,Emrullah Yilmaz,Jeffrey Yorio +205 more
TL;DR: A randomised, phase 3 study of participants with untreated locally incurable recurrent or metastatic HNSCC done at 200 sites in 37 countries finds that pembrolizumab alone improved overall survival and progression-free survival and cetuximab with chemotherapy improved Overall survival in the total population.
Journal ArticleDOI
Phase III Trial of Bevacizumab Plus Interferon Alfa-2a in Patients With Metastatic Renal Cell Carcinoma (AVOREN): Final Analysis of Overall Survival
Bernard Escudier,Joaquim Bellmunt,Sylvie Negrier,Emilio Bajetta,Bohuslav Melichar,Sergio Bracarda,Alain Ravaud,Sophie Golding,S. Jethwa,Vesna Sneller +9 more
TL;DR: Bvacizumab plus IFN is active as first-line treatment in patients with mRCC, and considering the overall sequence of therapy when selecting first- line therapy may optimize patient benefit.